Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity

被引:65
|
作者
Singh, Nirbhai [1 ]
Tiem, Michelle [1 ]
Watkins, Ryan [1 ]
Cho, Yang Kyung [2 ]
Wang, Ying [1 ]
Olsen, Thomas [1 ]
Uehara, Hironori [1 ]
Mamalis, Christina [1 ]
Luo, Ling [3 ]
Oakey, Zackery [1 ]
Ambati, Balamurali K. [1 ]
机构
[1] Univ Utah, Moran Eye Ctr, Salt Lake City, UT 84132 USA
[2] Catholic Univ Korea, St Vincent Hosp, Suwon, Gyeonggi Provin, South Korea
[3] PLA, Hosp 306, Beijing, Peoples R China
基金
美国国家卫生研究院;
关键词
MURINE PENETRATING KERATOPLASTY; LYMPHATIC VESSELS; FACTOR-C; ENDOGENOUS INHIBITOR; VEGF RECEPTOR-3; TRANSGENIC MICE; GRAFT-SURVIVAL; LYMPHANGIOGENESIS; ANGIOGENESIS; EXPRESSION;
D O I
10.1182/blood-2012-08-453043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Corneal transparency is a prerequisite for optimal vision and in turn relies on an absence of blood and lymphatic vessels, which is remarkable given the cornea's proximity to vascularized tissues. Membrane-bound vascular endothelial growth factor receptor 3 (VEGFR-3), with its cognate ligand vascular endothelial growth factor C (VEGF-C), is a major mediator of lymphangiogenesis. Here, we demonstrate that the cornea expresses a novel truncated isoform of this molecule, soluble VEGFR-3 (sVEGFR-3), which is critical for corneal alymphaticity, by sequestering VEGF-C. sVEGFR-3 binds and sequesters VEGF-C, thereby blocking signaling through VEGFR-3 and suppressing lymphangiogenesis induced by VEGF-C. sVEGFR-3 knockdown leads to lymphangiogenesis and hemangiogenesis in the mouse cornea, while overexpression of sVEGFR-3 inhibits lymphangiogenesis and hemangiogenesis in a murine suture injury model. Pax6(+/-) mice spontaneously develop corneal and lymphatic vessels and are deficient in sVEGFR-3. sVEGFR-3 suppresses hemangiogenesis by blocking VEGF-C-induced phosphorylation of VEGFR-2. Overexpression of sVEGFR-3 leads to a 5-fold increase in corneal transplant survival in mouse models. sVEGFR-3 holds promise as a molecule to control and regress lymphatic-vessel-based dysfunction. Therefore, sVEGFR-3 has the potential to protect the injured cornea from opacification secondary to infection, inflammation, or transplant rejection.
引用
收藏
页码:4242 / 4249
页数:8
相关论文
共 50 条
  • [31] Expression of Soluble Vascular Endothelial Growth Factor Receptor-2 and Its Effect on Proliferation of Vascular Endothelial Cells
    Wang Song
    Lu Jian-nan
    Xu Yan
    Liu Lu-cheng
    Wu Jiang
    Shao Guo-guang
    Sun Xin
    CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2012, 28 (02) : 245 - 248
  • [32] Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung
    Janvier, A
    Nadeau, S
    Baribeau, J
    Perreault, T
    CRITICAL CARE MEDICINE, 2005, 33 (04) : 860 - 866
  • [33] Monitoring of vascular endothelial growth factor and its soluble receptor levels in early trauma
    Guo, Jianying
    Yan, Wenwen
    Yang, Yong
    Wang, Zhiyong
    Tian, Fengjun
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2017, 82 (04): : 766 - 770
  • [34] Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis
    Tsao, Po-Nien
    Chan, Feng-Tsan
    Wei, Shu-Chen
    Hsieh, Wu-Shiun
    Chou, Hung-Chieh
    Su, Yi-Ning
    Chen, Chien-Yi
    Hsu, Wen-Ming
    Hsieh, Fon-Jou
    Hsu, Su-Ming
    CRITICAL CARE MEDICINE, 2007, 35 (08) : 1955 - 1960
  • [35] Vascular endothelial growth factor:an essential neurotrophic factor for motoneurons?
    Paula M.Calvo
    Angel M.Pastor
    Rosa R.de la Cruz
    Neural Regeneration Research, 2018, 13 (07) : 1181 - 1182
  • [36] Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors
    Artini, Paolo Giovanni
    Ruggiero, Maria
    Monteleone, Patrizia
    Carpi, Angelo
    Cristello, Francesca
    Cela, Vito
    Genazzani, Andrea Riccardo
    BIOMEDICINE & PHARMACOTHERAPY, 2008, 62 (06) : 373 - 377
  • [37] Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences
    Tsatsaris, V
    Goffin, F
    Munaut, C
    Brichant, JFO
    Pignon, MR
    Noel, A
    Schaaps, JP
    Cabrol, D
    Frankenne, F
    Foidart, JM
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11): : 5555 - 5563
  • [38] Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients
    Gomez-Bernal, Fuensanta
    Fernandez-Cladera, Yolanda
    Carlos Quevedo-Abeledo, Juan
    Garcia-Gonzalez, Maria
    Gonzalez-Rivero, Agustin F.
    De Vera-Gonzalez, Antonia
    Martin-Gonzalez, Candelaria
    Gonzalez-Gay, Miguel A.
    Ferraz-Amaro, Ivan
    BIOMOLECULES, 2022, 12 (12)
  • [39] Vascular endothelial growth factor and its soluble receptor in infants with congenital cardiac disease
    Pohl-Schickinger, Anja
    Koehne, Petra
    Schmitz, Thomas
    Schmitt, Katharina R. L.
    Hubler, Michael
    Redlin, Matthias
    Berger, Felix
    Stiller, Brigitte
    CARDIOLOGY IN THE YOUNG, 2010, 20 (05) : 505 - 508
  • [40] Vascular endothelial growth factor: an essential neurotrophic factor for motoneurons?
    Calvo, Paula M.
    Pastor, Angel M.
    de la Cruz, Rosa R.
    NEURAL REGENERATION RESEARCH, 2018, 13 (07) : 1181 - 1182